Taysha joins lay­off wave as Dal­las biotech paus­es most of its R&D work

4 years ago
People
R&D

Pear Ther­a­peu­tics sets the stage for a fruit­ful 2022, fore­cast­ing a five-fold boost in rev­enue

4 years ago
Pharma

Q&A: Lon­za­'s Chris­t­ian Dowdeswell talks HPA­PIs and the Oas­mia deal

4 years ago
Manufacturing

Bay­er to dump $2.26B in­to man­u­fac­tur­ing re­align­ment as it says good­bye to some sites

4 years ago
R&D
Manufacturing

AGC to use re­cent­ly-ex­pand­ed Ger­many site for peanut al­ler­gy drug tri­als

4 years ago
Manufacturing

In­dia of­fers in­cen­tives to do­mes­tic drug­mak­ers for APIs; Af­ter PhI­II tri­als, Tai­ho li­cens­es Arokaris in Japan

4 years ago
Manufacturing

A ran­somware at­tack on a Pfiz­er ven­dor trig­gered over­pay­ments to hourly staffers — and now the phar­ma gi­ant wants ...

4 years ago
R&D

On a mis­sion to re­shape Sanofi, Paul Hud­son takes a slight pay cut

4 years ago
People
Pharma

Can­cer drug de­vel­op­ers will learn from the blaz­ing speed of the Covid-19 vac­cine race, FDA lead­ers say

4 years ago
FDA+
Coronavirus

Roger Perl­mut­ter re­cruits an­oth­er Mer­ck vet to his new start­up: for­mer CEO Ken Fra­zier

4 years ago
People

Bel­gian VC be­hind Ab­b­Vie-owned Syn­de­si clos­es sec­ond in­vest­ment fund, se­cur­ing nine-fig­ure raise

4 years ago
Financing

Mukher­jee and Vale's Myeloid teams up with David Li­u's Prime Med­i­cine in race against Tessera

4 years ago
Startups
Deals

Up­dat­ed: SEC chair de­nies a deal to pre­vent Chi­nese com­pa­ny delist­ing is close — re­ports

4 years ago
China
Pharma

Pe­ter Thiel's Mithril leads ef­fort to elect a new slate of in­sid­ers to the board of trou­bled Covid play­er Ada­gio

4 years ago
People
Deals

From pub­lic re­la­tions in­to broad­er mar­ket­ing, GMHC re­brands to re­flect agency net­work evo­lu­tion

4 years ago
Pharma
Marketing

Ver­tex claims suc­cess on its non-opi­oid pain drug, push­ing can­di­date in­to piv­otal tri­als

4 years ago
R&D

Cosela mak­er's ear­ly em­ploy­ees aim to repli­cate 'blue­print' at a new biotech — with an old G1 as­set

4 years ago
Financing
Startups

$35 month­ly in­sulin cap: Re­pub­li­cans de­cry how White House, Dems plan to pay for it

4 years ago
Pharma

Af­ter an RTF and some stern warn­ings, FDA slaps Cy­to­Dyn with two clin­i­cal holds

4 years ago
FDA+

At­ten­tion biotech his­to­ry: Gink­go pours $700M+ on just 2 ex­ecs

4 years ago
Financing

Mer­ck chop­ping 140-plus staffers out of Ac­celeron in wake of $11.5B buy­out

4 years ago
People
Pharma

Ex­clu­sive: Fol­low­ing a se­vere set­back, Bridge­Bio brings out the bud­get axe to chop staff but keeps qui­et on the ...

4 years ago
Pharma

FDA ad­vi­sors vote 6-4 against Amy­lyx's ALS drug, fur­ther dim­ming its hope for reg­u­la­to­ry suc­cess

4 years ago
R&D
FDA+

Safe­ty con­cerns lead FDA to re­ject Ake­bi­a's kid­ney drug

4 years ago
Pharma
FDA+
First page Previous page 557558559560561562563 Next page Last page
A service from the Financial Times